ClinicaliQ Trial Snapshot
- A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). — Recruiting • Phase II / Phase III • NCT06412666.
- Aficamten improves symptoms and safety in children with obstructive hypertrophic cardiomyopathy, a serious heart muscle condition.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Conditions: Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy Interventions: Aficamten, Placebo Lead Sponsor: Cytokinetics Planned Enrollment: 55 participants